Table 3 Differences in renal function during therapy
From: Evaluation of intravenous voriconazole in patients with compromised renal function
Parameter | Voriconazole | Caspofungin | Fluconazole | ||||||
|---|---|---|---|---|---|---|---|---|---|
Baseline Clcr (mL/min) | <30 | 30–50 | p-value | <30 | 30–50 | p-value | <30 | 30–50 | p-value |
n (%) | 6 (31.6) | 13 (68.4) | -- | 33 (60.0) | 22 (40.0) | -- | 27 (50.0) | 27 (50.0) | -- |
Maximum ↑ Scr, mg/dL (SD) | 0.68 (1.01) | 0.62 (0.54) | 0.88 | 1.17 (1.9) | 0.15 (0.78) | 0.02 | 2.6 (2.7) | 2.0 (2.0) | 0.33 |
Lowest Clcr during treatment, mL/min (SD) | 16.8 (3.7) | 31.7 (7.3) | 0.0002 | 15.8 (6.0) | 34.6 (7.7) | <0.0001 | 13.9 (5.1) | 24.3(8.2) | <0.0001 |
Clcr at EOT, mL/min (SD) | 28.7 (18.1) | 50.3(27.8) | 0.11 | 46.4(43.1) | 59.5(28.4) | 0.21 | 30.6(19.2) | 49.0(22.6) | 0.0025 |
% Change Clcr (Lowest-SOT)/SOT (SD) | −24.6 (12.6) | −19.6 (13.4) | 0.45 | −19.4(17.7) | −15.6(15.1) | 0.41 | −35.3(18.4) | −37.5(20.7) | 0.68 |
Renal dysfunction, n (%) | 3 (50.0) | 4 (30.8) | 0.42 | 12 (36.4) | 3 (13.6) | 0.06 | 17 (63.0) | 15 (55.6) | 0.58 |